We found that group 3 (KRAS- and/or PIK3CA-mutant; MSI–; CIN+; TP53-wild-type) patients had poor survival, whereas all the other cancer groups showed no significant differences in survival (hazard ratio = 1.59, 95% CI 1.13–2.24, p = 0.008; Cox proportional hazards, group 3 versus all other groups; Figure 3). This evidence concerns the gene TP53 and cancer.